A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy
Prostate Cancer and Prostatic Diseases advance online publication, January 12 2016.
doi:10.1038/pcan.2015.59
Authors: A J Armstrong, S Halabi, P Healy, W R Lee, B F Koontz, J W Moul, K Mundy, P Creel, S Wood, K Davis, M A Carducci, M Stein, C Hobbs, B Reimer, M Nguyen, M Anand, L Bratt, S Kim, P T Tran, D J George & on behalf of Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC)
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: A J ArmstrongS HalabiP HealyW R LeeB F KoontzJ W MoulK MundyP CreelS WoodK DavisM A CarducciM SteinC HobbsB ReimerM NguyenM AnandL BrattS KimP T TranD J George Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Docetaxel | Prednisone | Prostate Cancer | Radiation Therapy | Taxotere | Urology & Nephrology